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OBJECTIVES: Chronic pain is a common and universal phenomenon that appears
at all ages and in all populations. It has a substantially impact on the quality of
patients’ daily life as well as their physical and mental function. The objective of
this study was to document attributes of a pain medication that are relevant from
the perspective of patients with chronic pain. METHODS: In a first step literature
review, focus groups with patients and one to one interviews with highly accepted
experts in the field of indication were conducted to identify relevant treatment
attributes of a pain medication. A pretest was conducted to verify the structure of
relevant and dominant attributes using factor analysis and choosing the most
frequent mentioned representative of each factor. The discrete choice experiment
(DCE) itself used a self administered survey including sociodemographics and an
indication specific parameter (pain). For statistical data analysis of the DCE, a ran-
dom effect logit model was used and coefficients were presented. RESULTS: In a
first step we detected 36 attributes. Factor analysis revealed seven remaining at-
tributes. A total of N1324 German patients participated in the self administered
survey, resulting in the following ranking of relevant attributes for treatment de-
cision: “no character change”, “less nausea and vomiting”, “pain reduction” (Coef-
ficient:  0.9 for all attributes, “high impact”); “rapid effect”, “less danger of addic-
tion” (Coefficient  0.5, “middle impact”); “applicability with comorbidity”
(Coefficient: 0.3), “improvement of quality of sleep” (Coefficient 0.25). All attri-
butes were highly significant (p  0.001). CONCLUSIONS: Due to the subjective
nature of pain, the management of chronic pain needs to be patient centered.
Therefore an understanding of patient preferences is essential for inclusion in
treatment decisions. In summary, DCE and direct assessment proved to be valid
instruments to elicit treatment preferences in chronic pain treatment.
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OBJECTIVES: The TRIM-Weight is a Patient-Reported Outcome (PRO) questionnaire
designed to assess the efficacy and tolerability of weight loss medication. The
objective of this study was to produce translations into number of languages that
are conceptually equivalent to the original and to other language versions, ensur-
ing the validity of the translations within the target cultures. METHODS: The stan-
dard linguistic validation methodology was followed: two forward translations
with reconciliation, two back translations and review, developer review, cognitive
interviews with five obese people for each language, and proof reading. RESULTS:
Numerous cultural and linguistic issues became apparent throughout the transla-
tion process, including the following: The term for ‘craving’ proved difficult to
translate into Spanish, Italian, French (France) and French (Canada). The develop-
er’s input and cognitive debriefing interviews were used to find appropriate termi-
nology to convey the intended meaning. For example, it had to be specified in
French (France) that this related to one particular food; ’Jitteriness’ was mentioned
in the scale as a physical side-effect of the drug; this word was problematic in
Dutch (where the translator had to use a term related to ‘trembling’), and Brazilian
Portuguese (where the translator used a term related to being physically anxious
and unable to relax); Brazilian respondents had difficulty understanding that they
must respond only concerning prescription weight loss medication and the related
instruction had to be underlined to clarify this; several vocabulary problems oc-
curred, e.g. finding terms for ‘isolated’ in Russian, ‘embarrassment’ in Brazilian
Portuguese and ‘weight loss plateaus’ in Austria German. Each issue was discussed
until a suitable alternative was found which could be tested in cognitive interviews
with patients. CONCLUSIONS: The TRIM-Weight questionnaire was translated and
linguistically validated using a rigorous translation process. A number of cultural
and linguistic issues became apparent and were resolved. TRIM-Weight is now
validated for use in multinational trials.
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OBJECTIVES: As the incidence of obesity continues to rise, there is pressure to find
and evaluate new weight loss interventions; understanding the impact of obesity
and weight loss on patients is an invaluable part of this process. We aimed to
examine associations among patient characteristics, self-reported depression, vi-
tality and the obesity and weight-loss quality-of-life (OWL-QOL) instruments in a
population of overweight and obese patients. METHODS: We analysed baseline
data from a clinical trial involving patients with body mass index (BMI) between
27–45kg/m2. Data included: patient demographics; obesity measures including
BMI, weight and body composition; responses to the OWL-QOL questionnaire; re-
sponses to the Patient Health Questionnaire (PHQ), assessing depression; and re-
sponses to the SF-36 vitality subscale. Least angle regression (LAR) was used to
select the most relevant obesity measures to include in multivariable regression
models. Univariate associations were examined using Spearman’s correlations.
RESULTS: Baseline data were available for 341 patients with a mean age of 44.2
(SD10.7) years, mean BMI of 35.2 (SD4.67) kg/m2, and mean OWL-QOL total score
of 55.3 (SD24.2). 83.3% were female. LAR showed that among obesity measures,
percentage of total fat was most significantly associated with the OWL-QOL total
score. Based on Spearman’s correlations, the OWL-QOL total score was signifi-
cantly correlated with gender (
0.233, p0.001), total fat (
-0.264, p0.001), PHQ
(
-0.138, p0.035), and vitality (
0.456, p0.001). In the final model (R20.34),
vitality (0.55, p0.001), female gender (-8.71, p0.026) and race/ethnicity
(12.3, African American versus Other, 1.08 White versus Other; p0.002 for
both comparisons), but not percentage of total fat, were significantly associated
with the OWL-QOL total score. CONCLUSIONS: The OWL-QOL was significantly
associated with gender, race/ethnicity and vitality. Importantly, based on LAR,
percentage of total fat was more significantly associated with the OWL-QOL total
score than other obesity measures, including BMI.
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OBJECTIVES: A previous survey distributed in Europe and the US found that lupus
affects patients’ career, physical well-being and everyday living. The LEO survey
was developed to explore further the effect of lupus on work productivity, fatigue
and health-related quality of life (HRQoL) in Europe. METHODS: The survey had
four sections. Section 1 included patient-developed questions on demographics,
lupus diagnosis and impact of lupus on work and career. Sections 2–4 used lupus-
specific patient-reported outcomes (PRO) instruments to assess work impairment
(Work Productivity and Activity Impairment Questionnaire, Lupus V2.0), fatigue
(lupus-specific Fatigue Severity Scale) and HRQoL (LupusQoL). The survey was
available May–August 2010 and in five European languages. RESULTS: A total of
1566 participants with self-reported lupus completed the survey: from France
(n139), Germany (n537), Italy (n357), Spain (n267) and the UK (n266). Most
were female (93%, 1440/1557) and aged 26–55 years (81%, 1253/1550). In section 1,
over two-thirds (70%, 1028/1475) of participants reported that lupus affected their
career (highest UK, 79% [199/252]; lowest France, 56% [73/131]). Of these, 31% (288/
928) now work flexible hours, 29% (265/928) applied for sick leave, 24% (219/928)
applied for social or disability allowance and 17% (156/928) changed career. Of
those who reduced work hours, almost a quarter (23%, 150/646) had to reduce by
75%. In the WPAI assessment, participants reported missing an average of 13%
(SD24.2) of their working time because of lupus. At work, productivity was re-
duced by an average of 40% (SD25.8). Overall, an average of 43% (SD27.1) of total
work hours available to participants were lost due to lupus. Ability to carry out
non-work activities such as housekeeping, childcare and studying was, on average,
impaired by 56% (SD26.7). CONCLUSIONS: Lupus diminishes European patients’
likelihood of working and their productivity while at work. These findings empha-
sise the need for improved management of lupus.
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OBJECTIVES: Comparative studies between Euroqol-5D (EQ-5D) and Short-form 6D
(SF-6D) utilities have been performed for a number of diseases, but not for patients
with Pompe disease. Pompe disease is a rare disease (prevalence of 5/10,000).
Characteristic features of late onset Pompe disease are impaired ambulatory and
respiratory functioning. We compared the psychometric properties of EQ-5D and
SF-6D in these patients and assessed the convergent validity and the ability of the
instruments to discriminate with respect to functional capabilities and subjective
health.METHODS: EQ-5D utilities were calculated using the Dutch value set. EQ-5D
and SF-6D domains and utilities were compared by correlation coefficients and
descriptive statistics. We assessed whether EQ-5D and SF-6D were able to discrim-
inate between different levels of Pompe disease severity as defined by subjective
health status (SF36 rating scale and Visual Analogue Scale (VAS) divided into ter-
tiles) and functional capabilities (use of wheelchair and respiratory support).
RESULTS: Eighty-two patients (82% of the total Dutch Pompe population) com-
pleted both EQ-5D and SF-6D (average follow-up 3.8 observations; 3.1 years). Cor-
relations between theoretically related domains were highly significant and mod-
erately strong (range rho0.392 – rho0.632). The SF-6D domain “vitality” had no
EQ-5D counterpart. Utility values were comparable (mean EQ-5D  0.739; mean
SF-6D 0.710), and moderately correlated (r0.544). Discriminative properties of
EQ-5D and SF-6D were comparable; patients using wheelchair, or respiratory sup-
port and patients with a lower VAS score reported lower EQ-5D and SF-6D utilities.
CONCLUSIONS: The descriptive system of the SF-6D described Pompe disease
more accurate. Discriminative properties of EQ-5D and SF-6D outcomes were sim-
ilar in this population.
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OBJECTIVES: To investigate the cross-over effects on health-related quality of life
(HRQoL) in an randomized cross-over design study for hemophilia-A patients.
METHODS: HRQoL via SF-36 Health Survey was measured every 3 months in a
prospective, randomized, cross-over, investigator-initiated study comparing 6
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